Product Pipeline
Clinical Programs in Infectious Cardiomyopathy, PKD/PLD, and Oncology

Why Begin with Chronic Chagas Cardiomyopathy?

• Caused by a parasite containing a single, targetable mitochondrion

• Approximately 350,000 patients in the United States and an estimated 8 million worldwide

• Significant unmet medical need with limited therapeutic options

• Potential regulatory advantages as a neglected tropical disease indication

• ICM-20 has demonstrated clinical safety and biomarker activity in Phase I/IIa studies

• GMP formulation and scalable U.S.-based manufacturing infrastructure in place

Image of a Kissing Bug
Image of Romaña sign
Image of a Heart

Clinical Progress

ICM Therapeutics is advancing clinical and translational programs focused on mitochondrial-associated disease mechanisms.

• Phase I/IIa studies established the safety profile of ICM-20 and demonstrated encouraging biomarker signals
• Ongoing development efforts are focused on Phase IIb studies in infectious cardiomyopathy
• Additional programs are advancing in PKD/PLD and oncology

ICM’s broader therapeutic strategy is centered on developing small-molecule mitochondrial therapeutics for serious chronic diseases.